The Dasatinib compulsory license conundrum
The anticancer meds “nibs” (including Imatinib, Sunitinib, and Dasatinib) have always been mired in controversy. Recently Dasatinib made news when the economic times reported that “The Indian Patent Office has rejected Mumbai-based BDR Pharmaceutical’s application for compulsory licence on cancer drug Dasatinib, according to an affidavit filed by Bristol Myers Squibb, the patent holder for…